pan-Canadian Pharmaceutical Alliance (pCPA): September 2020 Trends and Insights
September 2020 Highlights:
- 1 product completed CADTH review
- 0 products initiated pCPA negotiations
- 2 negotiations were completed with an LOI
- 0 negotiations were closed without an LOI
- 1 file was closed without negotiation
Files Under pCPA Consideration:
CADTH issued 1 new recommendation in September (25 files as of September 30).
| PRODUCT | INDICATION | SPONSOR | HTA | REC’N* DATE |
|---|---|---|---|---|
| Zejula (niraparib) | Ovarian Cancer | GlaxoSmithKline | pCODR | 21 Sep |
* REC’N DATE = Date of CDEC Final Recommendation (CDR), Date Notification to Implement Issued (pCODR)
Negotiation Initiation:
The pCPA initiated 0 new negotiations in September (26 active negotiations as of September 30, 2020)
Completed/Closed Negotiations:
The pCPA completed 2 negotiations with a Letter of Intent (LOI) in September 2020.
| PRODUCT | INDICATION | SPONSOR | LOI DATE | TTN* |
|---|---|---|---|---|
| Adcetris
(brentuximab vedotin) |
Peripheral T-Cell Lymphoma | Seattle Genetics | 21 Sep | 80 |
| Admelog
(insulin lispro) |
Diabetes mellitus, type 1 & 2 | Sanofi-aventis | 30 Sep | 245 |
* TTN = Time to Negotiate in calendar days
Signals Decoded:
September saw the first successful negotiation of a Humalog biosimilar while Adcetris completed pCPA negotiations for a third indication.
Not Negotiated:
The pCPA declined to negotiate 1 file in September 2020.
| PRODUCT | INDICATION | SPONSOR | DECLINE DATE | TTD* |
|---|---|---|---|---|
| Tecentriq & Avastin (atezolizumab & bevacizumab) |
Non-Squamous Non-Small Cell Lung Cancer | Hoffman-La Roche | 1 Sep | 43 |
* TTD = Time to Decline in calendar days
Signals Decoded:
The Tecentriq & Avastin combination for Non-Squamous Non-Small Cell Lung Cancer received a “Do Not List” recommendation from pCODR.
To receive updates similar to this one please be sure to sign up for MORSE Signals, our free e-mail newsletter service.
